Table 2.
Characteristics of the study groups.
| SCZ n = 51 | SCZ-r n = 26 | BD-e n = 28 | |
|---|---|---|---|
| Males (%) | 64.7 | 50 | 57.14 |
| Age (mean yrs ± SD) | 40.33 ± 10.82 | 37.19 ± 11.63 | 41.29 ± 9.39 |
| Education (yrs mean ± SD) | 13.57 ± 3.05 | 14.19 ± 3.02 | 13.25 ± 5.07 |
| Illness Duration (yrs mean ± SD) | 17.8 ± 9.96 | 14.15 ± 9.99 | 16.29 ± 10.9 |
| Antipsychotic therapy | |||
| Typical antipsychotics % (N/Total) | 17.65 (9/51) | 19.23 (5/26) | 10.71 (3/28) |
| Atypical antipsychotics % (N/Total) | 64.71 (33/51) | 73.07 (19/26) | 85.71 (24/28) |
| Typical and Atypical antipsychotics % (N/Total) | 17.65 (9/51) | 7.69 (2/26) | 0 (0/28) |
| No antipsychotic treatment | 0 (0/51) | 0 (0/51) | 3.57 (1/28) |
| Chlorpromazine – equivalent daily dose – median (Range) | 400 mg (125–1,200) | 400 mg (125–1,200) | 300 mg (0–800) |
SCZ, Subjects affected by schizophrenia; SCZ-r, Subjects affected by schizophrenia with remitted positive symptoms; BD-e, Subjects affected by bipolar disorder-type I with psychotic features during a euthymic phase.